TriLink BioTechnologies Awarded Phase I Grant for a Second Hot Start PCR Project

SAN DIEGO, May 15 /PRNewswire/ -- TriLink BioTechnologies (TriLink), a leading provider of custom nucleic acid-based compounds, has been awarded a Small Business Innovation Research (SBIR) Phase I grant of approximately $100,000. In these Phase I studies, TriLink will investigate its second novel approach for Hot Start activation in PCR. This approach, which employs chemically-modified triphosphates to inhibit DNA polymerase activity until a thermal activation step, has already showed significant promise in the reduction of off-target amplification products in PCR. Proposed experimentation includes optimization of the Hot Start effect and further investigation in its benchtop applications. This is the second Phase I grant TriLink has been awarded for development of technology in the Hot Start PCR sector.

“This award is our third in the last two years. It is indicative of the success of our ongoing conversion from solely a manufacturing facility to a fully integrated discovery firm with its own production capabilities. We are about to launch our first major novel PCR product (CleanAmp(TM)) that resulted from one of the SBIR grants we received last year. We believe we will be able to launch a second product with significant implications for the PCR market by late 2008 as a result of this SBIR,” commented CEO Dr. Richard Hogrefe.

About TriLink

TriLink BioTechnologies, Inc. manufactures custom oligonucleotides, nucleoside triphosphates, and synthesis reagents for research and diagnostic laboratories. In addition, it offers radiolabeling services, custom chemistry, contract research services and GMP production facilities for oligos and small molecules. TriLink’s solutions help advance drug discovery and biomedical research. For more information visit www.trilinkbiotech.com or contact:

TriLink BioTechnologies

Lisa Olivier, 858-546-0004

lolivier@trilinkbiotech.com

TriLink BioTechnologies, Inc.

CONTACT: Lisa Olivier of TriLink BioTechnologies, Inc., +1-858-546-0004,lolivier@trilinkbiotech.com

MORE ON THIS TOPIC